COM:ITERIONTHERAPEUTICS
Iterion Therapeutics
- Privately Held
Description
Iterion Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel cancer therapeutics. The company's lead product, tegavivint, is a highly specific and potent first-in-class small molecule inhibitor of TBL1 (Transducin Beta-Like Protein 1), a novel downstream target of the canonical Wnt/beta-catenin signaling pathway.